Discover why biomarkers are critical in modern drug discovery and clinical trials, enabling better target validation.

Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 ...

Soo-Kyung and Jae Lee, whose daughter has FOXG1 syndrome, developed the gene therapy that could one day treat people with this severe disorder.

In today's ACT Brief, we examine why transparency in complex trial designs is essential for data confidence, how protocol structure—not operational effort—determines recruitment success, and the FDA's ...

Agentic AI could reshape drug development. In this interview, Dr. Claudio D’Ambrosio discusses how agentic AI can identify novel drug compounds, improve trial design, and reduce operational ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Organoids, assembloids, and organ-on-a-chip technologies represent transformative advances in the fields of drug discovery, precision medicine, and ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Clinical Trials suffer due to inherent inefficiencies in manual workflows built on fragmented systems. It's time for a ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...